2 research outputs found
Lung damage caused by COVID-19 and community-acquired pneumonia in children: Π‘omparative clinical and laboratory analysis
The study is devoted to the challenge of interpreting the lung damage associated with COVID-19 in children and the necessity for antimicrobial therapy in this disease. The aim of the research was a comparative analysis of clinical, radiological and laboratory signs in children with COVID19 and community-acquired pneumonia (CAP). Methods. The observational comparative study included medical records of 53 children with the lung damage at the age of 1 year 4 months up to 17 years old, hospitalized for the period from June to August 2020. All children were tested for Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) by polymerase chain reaction (PCR). 34 patients with SARS-CoV-2+ were diagnosed with COVID-19 and 19 children with SARS-CoV-2β were diagnosed with CAP. The assessment included medical history, clinical, laboratory and radiological changes. Results. Distinctive reliable clinical, laboratory, and X-ray signs of lung damage in COVID-19 compared to CAP were olfactory impairment (26%), bilateral lung damage (23%), erythrocytosis, leukopenia (20.6%), granulocyto- and monocytopenia, lower levels of reactive protein (CRP). Irrational prescribing of antibiotics (94%) was detected in the group of patients with COVID-19. Conclusion. We established the reliable clinical, laboratory and radiological features of COVID-19 in children, which indicate the viral nature of lung damage.ΠΡΠ½ΠΎΠ²Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° ΠΈΠ½ΡΠ΅ΡΠΏΡΠ΅ΡΠ°ΡΠΈΠΈ ΠΏΠ΅Π΄ΠΈΠ°ΡΡΠ°ΠΌΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
Ρ Π΄Π΅ΡΠ΅ΠΉ ΠΏΡΠΈ COronaVIrus Disease-2019 (COVID-19) ΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΏΡΠΈ ΡΡΠΎΠΌ Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ. Π¦Π΅Π»ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»ΡΡ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
, ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
(Π Π) ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ
ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ² COVID-19 ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
ΠΈ Π²Π½Π΅Π±ΠΎΠ»ΡΠ½ΠΈΡΠ½ΠΎΠΉ ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΠΈ (ΠΠ) Ρ Π΄Π΅ΡΠ΅ΠΉ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΡΠ°ΠΌΠΊΠ°Ρ
Π½Π°Π±Π»ΡΠ΄Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π΄Π°Π½Π½ΡΠ΅ ΠΈΡΡΠΎΡΠΈΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π΄Π΅ΡΠ΅ΠΉ (n = 53) Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 1 Π³ΠΎΠ΄Π° 4 ΠΌΠ΅Ρ. Π΄ΠΎ 17 Π»Π΅Ρ Ρ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ Π»Π΅Π³ΠΊΠΈΡ
, Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Π·Π° ΠΏΠ΅ΡΠΈΠΎΠ΄ Ρ ΠΈΡΠ½Ρ ΠΏΠΎ Π°Π²Π³ΡΡΡ 2020 Π³. Π£ Π²ΡΠ΅Ρ
Π΄Π΅ΡΠ΅ΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ (ΠΠ¦Π ) ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π½Π° Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2), ΠΏΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Ρ SARS-CoV-2+ (n = 34) ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ Π΄ΠΈΠ°Π³Π½ΠΎΠ· Π‘OVID-19, ΠΏΡΠΈ SARS-CoV-2β (n = 19) Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠΎΠ²Π°Π½Π° ΠΠ. ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΡΠ°ΠΊΠΆΠ΅ Π°Π½Π°ΠΌΠ½Π΅Π· Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅, Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΈ Π΄Π°Π½Π½ΡΠ΅ Π Π. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠ»ΠΈΡΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠΌΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎΠ»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌΠΈ ΠΈ Π Π-ΠΏΡΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ Π»Π΅Π³ΠΊΠΈΡ
ΠΏΡΠΈ COVID-19 ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΠ ΡΠ²Π»ΡΠ»ΠΈΡΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΎΠ±ΠΎΠ½ΡΠ½ΠΈΡ (26 %), Π΄Π²ΡΡΡΠΎΡΠΎΠ½Π½Π΅Π΅ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ Π»Π΅Π³ΠΊΠΈΡ
(23 %), ΡΡΠΈΡΡΠΎΡΠΈΡΠΎΠ·, Π»Π΅ΠΉΠΊΠΎΠΏΠ΅Π½ΠΈΡ (20,6 %), Π³ΡΠ°Π½ΡΠ»ΠΎ- ΠΈ ΠΌΠΎΠ½ΠΎΡΠΈΡΠΎΠΏΠ΅Π½ΠΈΡ, Π½ΠΈΠ·ΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π‘-ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ°. Π Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ COVID-19 Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π½Π΅ΡΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² (94 %). ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠ΅ ΠΈ Π Π-ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ COVID-19 Ρ Π΄Π΅ΡΠ΅ΠΉ, ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡΠΈΠ΅ ΠΎ Π²ΠΈΡΡΡΠ½ΠΎΠΌ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠΈ Π»Π΅Π³ΠΊΠΈ